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PA-02. CORRELATIONS BETWEEN MULTIPLE MOLECULAR 
MARKERS' EXPRESSION AND SURVIVAL IN PATIENTS 
WITH GLIOBLASTOMA MULTIFORME TREATED WITH 
THE CURRENT STANDARD TREATMENT 
Daniela A. Bota,1 Kathy L. Newell,2 Marsha Danley,2 Marilyn Davis,2 
Richard Dubinsky,1 and Sarah A. Taylor3; 1Department of Neurology, 2Department of Pathology, and 'Division of Clinical Oncology, University 
of Kansas Medical Center, KS, USA 
Glioblastoma multiforme (GBM) is an aggressive cancer. The median 
reported survival for patients with this disease is between 1 and 2 years. 
However, there is high heterogeneity in patients' response to treatment, 
disease-free survival, and overall survival (OS), which cannot be accu­
rately predicted at the time of diagnosis. Moreover, most GBM studies 
have included patients that received different treatments, making it hard to 
extrapolate the data to the standard treatment. Our objective was to study 
the OS-predictive value of various molecular markers representing differ­
ent pathways of oncogenesis in a group of patients with primary GBM that 
received the current standard of treatment. We identified 19 GBM patients 
who were treated in the KU Oncology Center between January 1, 2000, and 
July 30, 2004, with surgical resection followed by conformal radiation and 
temozolomide per Stupp. All patients but one continued on temozolomide 
until progression. The antibodies used targeted different pathways, such 
as proliferation (MIB-1), tumor progression and resistance to apoptotic 
signals (p53), cell migration and invasion (MMP2), control of cell cycle 
and transcriptional regulation (MAPK), proliferation (EGFR), angiogen­
esis (VEGF), and resistance to temozolomide (O-6-methylguanine DNA 
transferase). Both semiquantitative and quantitative (ACIS II, Clarient, San 
Juan Capistrano, CA, and ISi) methods were used to evaluate the immuno­
stained sections, and these results were correlated to length of survival. The 
data were analyzed with PC-SAS software (SAS Institute, Cary NC) using 
stepwise logistic regression analysis for survival (defining trends for P < 
0.1). The patients included in our study had a median age of 53 years (range, 
29-71 years), a median performance score of 80% (range, 50-100%), and a 
mean survival of 601 days (range, 159-1,189 days). The only markers that 
showed trends toward correlating with increased survival were high p53 
levels (P = 0.07) and low MAPK (P = 0.08), although low MMP2 was close 
to the threshold (P = 0.14). The other molecular markers, including EGFR, 
VEGF and MGMT, did not correlate with patient survival. Of the four 
patients who lived more than 30 months, all had negative EGFR staining, 
and three had negative p53 and very low or absent MGMT. This pilot study 
suggests that the most important pathways for tumor activity in patients 
treated with temozolomide are those involved in apoptosis (p53 ), cell cycle 
control (MAPK), and possibly local migration (MMP2). The ability to pre­
dict patient survival and response to treatment at the time of the initial 
diagnosis would be an invaluable tool both for planning future therapies 
and for patients' treatment and quality-of-life decisions. We will further 
test whether a panel of 10 molecular markers involved in different aspects of 
tumorigenesis can be used to achieve greater accuracy in predicting patients' 
long-term prognosis. 
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